Evidence map›Paper›PMID 35417813›Full record

ArticleTranslational oncology2022

The clinical significance of epigenetic and RNAPII variabilities occurring in clear cell renal cell carcinoma as a potential prognostic marker.

Nóra Ördög, Barbara N Borsos, Hajnalka Majoros, Zsuzsanna Ujfaludi, Gabriella Pankotai-Bodó, Sarolta Bankó, Farkas Sükösd, Levente Kuthi, Tibor Pankotai

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Nóra ÖrdögInstitute of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, 1 Állomás Street, Szeged H-6725, Hungary.
Barbara N BorsosInstitute of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, 1 Állomás Street, Szeged H-6725, Hungary.
Hajnalka MajorosInstitute of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, 1 Állomás Street, Szeged H-6725, Hungary.
Zsuzsanna UjfaludiInstitute of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, 1 Állomás Street, Szeged H-6725, Hungary.
Gabriella Pankotai-BodóInstitute of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, 1 Állomás Street, Szeged H-6725, Hungary.
Sarolta BankóInstitute of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, 1 Állomás Street, Szeged H-6725, Hungary.
Farkas SükösdInstitute of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, 1 Állomás Street, Szeged H-6725, Hungary.
Levente KuthiInstitute of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, 1 Állomás Street, Szeged H-6725, Hungary. Electronic address: kuthi.levente@med.u-szeged.hu.
Tibor PankotaiInstitute of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, 1 Állomás Street, Szeged H-6725, Hungary. Electronic address: pankotai.tibor@szte.hu.
University of Szeged · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients diagnosed with clear cell renal cell carcinoma (ccRCC) have poor prognosis for recurrence and approximately 30-40% of them will later develop metastases. For this reason, the appropriate diagnosis and the more detailed molecular characterisation of the primary tumour, including its susceptibility to metastasis, are crucial to select the proper adjuvant therapy by which the most prosperous outcome can be achieved. Nowadays, clinicopathological variables are used for classification of the tumours. Apart from these, molecular biomarkers are also necessary to improve risk classification, which would be the most beneficial amongst modern adjuvant therapies. As a potential molecular biomarker, to follow the transcriptional kinetics in ccRCC patients (n=30), we analysed epigenetic changes (γH2A.X, H3K4me

Indexed as

ccRCCepigeneticsH3K4me(3) and H3K9me(3)Renal cell carcinomaRNAPIIγH2A.X

Identifiers

PMID35417813
PMCPMC9018449
OpenAlexW4223591205

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.